GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satsuma Pharmaceuticals Inc (NAS:STSA) » Definitions » PS Ratio

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) PS Ratio : (As of May. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Satsuma Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Satsuma Pharmaceuticals's share price is $1.10. Satsuma Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00. Hence, Satsuma Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for Satsuma Pharmaceuticals's PS Ratio or its related term are showing as below:

STSA's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.03
* Ranked among companies with meaningful PS Ratio only.

Satsuma Pharmaceuticals's Revenue per Sharefor the three months ended in Mar. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00.

Back to Basics: PS Ratio


Satsuma Pharmaceuticals PS Ratio Historical Data

The historical data trend for Satsuma Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satsuma Pharmaceuticals PS Ratio Chart

Satsuma Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PS Ratio
Get a 7-Day Free Trial - - - - -

Satsuma Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Satsuma Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Satsuma Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satsuma Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satsuma Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Satsuma Pharmaceuticals's PS Ratio falls into.



Satsuma Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Satsuma Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.10/0
=

Satsuma Pharmaceuticals's Share Price of today is $1.10.
Satsuma Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Satsuma Pharmaceuticals  (NAS:STSA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Satsuma Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Satsuma Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
400 Oyster Point Boulevard, Suite 221, South San Francisco, CA, USA, 94080
Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Executives
Mutya Harsch director C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Shin Nippon Biomedical Laboratories, Ltd. 10 percent owner 2438 MIYANOURA-MACHI, KAGOSHIMA CITY, KAGOSHIMA M0 891-1394
Thomas P Soloway director C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Ken Takanashi director, 10 percent owner C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Detlef Albrecht officer: Chief Medical Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Thomas P. O'neil officer: Chief Financial Officer SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Rajeev M. Shah director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
John A Kollins director, officer: President and CEO SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Headlines